Abstract
The effect of glucagon-like peptide-1 receptor agonists liraglutide and semaglutide on cardiovascular and renal outcomes across baseline blood pressure categories: Analysis of the LEADER and SUSTAIN 6 trials
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have